Key Takeaways How to find the best cheap stocks on Wall Street to buy in December and in 2026.Buy surging top-ranked $10 biotech stock FOLD before it breaks out?The Fed is projected to cut interest rates again on Wednesday. On top of that, the earnings outlook for 2026 remains very strong. This backdrop should leave investors feeling bullish in December and ready to add to their portfolios now and in the early weeks of 2026.Today, we explore how investors can find the best-in-class cheap stocks trading for ...

Core Insights - Structure Therapeutics Inc. (NASDAQ:GPCR) achieved a new 52-week high following positive topline results from its clinical program for the obesity treatment candidate, aleniglipron [1][3] - The stock price surged to $94.90 during intra-day trading, ultimately closing at $69.98, reflecting a 102.49% increase [2] - Patients receiving a 120mg daily dose of aleniglipron experienced an 11.3% weight loss over 36 weeks, while those on a 240mg dose lost up to 15.3% [2] Clinical Trial Progress - Aleniglipron showed a tolerability profile consistent with GLP-1 receptor agonists and a favorable off-target safety profile [3] - Structure Therapeutics plans to advance to Phase 3 of the clinical trial by mid-2026, following discussions with the FDA in the first half of next year to finalize the trial design [4][5] - The Phase 3 trial is expected to start with a titration dose of 2.5 mg, evaluating multiple doses up to 240 mg [4] Strategic Outlook - The CEO of Structure Therapeutics, Raymond Stevens, emphasized the potential of aleniglipron to become a foundational oral therapy for obesity, highlighting its accessibility, scalability, and combinability [5]

Core Viewpoint - Kymera Therapeutics, Inc. (NASDAQ:KYMR) has experienced significant stock performance, reaching an all-time high following positive clinical trial results for its eczema treatment, KT-621 [1][3]. Stock Performance - During intra-day trading, Kymera's stock price peaked at $103 before closing at $94.30, reflecting a 41.55 percent increase [2]. Clinical Trial Results - The clinical trial for KT-621 involved 22 patients over four weeks, resulting in a nearly complete elimination of the transcription factor STAT6, which is associated with allergic inflammation, by 98 percent in blood and 94 percent in skin [3]. Fundraising Plans - Kymera Therapeutics announced plans to raise $500 million through the issuance of new shares, with the potential to increase this amount to $575 million [4]. - The proceeds from this offering will be allocated to finance ongoing preclinical and clinical degrader programs, as well as for working capital and general corporate purposes [4]. Underwriter Option - In conjunction with the share offering, Kymera granted underwriters the option to purchase an additional $75 million at the public offer price [5].

Core Insights - Dyne Therapeutics, Inc. (NASDAQ:DYN) experienced a significant stock increase of 9.47% to $22.20 following positive clinical trial results for its therapy candidate, zeleciment rostudirsen, aimed at treating Duchenne muscular dystrophy (DMD) [1][3] Clinical Trial Results - The drug candidate successfully met its primary endpoint, showing a 5.46% increase in muscle-content adjusted dystrophin levels and functional improvements across multiple clinical endpoints [2] - The therapy demonstrated a high level of dystrophin expression, a favorable safety profile, and a convenient monthly dosing regimen, indicating its potential to transform DMD care [3] Safety and Trial Details - The therapy was generally considered safe and tolerable, with common adverse effects reported as fever and headache [4] - The clinical trial involved 32 males with DMD, aged 4 to 16, who had mutations suitable for exon 51 skipping [4] Future Plans - Dyne Therapeutics is on track to submit for accelerated approval in Q2 2026, with plans to launch the therapy in Q1 2026 [4]

Core Insights - Wave Life Sciences Ltd. experienced a stock increase due to positive data from the INLIGHT trial of WVE-007 for weight loss, showing significant improvements in body composition [1][2] - The company announced a public offering of $250 million to support its research pipeline and operational growth [3][4] - Analysts have become more optimistic about Wave Life Sciences, with several firms raising ratings and price forecasts significantly [5] Group 1: Clinical Trial Results - A single 240 mg dose of WVE-007 resulted in a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass after three months [2] Group 2: Public Offering - Wave Life Sciences initiated a $250 million underwritten public offering of ordinary shares and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares [3][4] - The offering aims to bolster the company's research and operational capabilities, although completion is subject to market conditions [4] Group 3: Analyst Ratings - RBC Capital upgraded Wave Life Sciences to Outperform, raising its price target from $9 to $27 [5] - Clear Street maintained a Buy rating and increased its price forecast from $22 to $47 [5] - Cantor Fitzgerald kept an Overweight rating and raised its price target from $12 to $34 [5] Group 4: Stock Performance - Wave Life Sciences shares rose by 14.52% to $21.21, reaching a new 52-week high [6]

Core Viewpoint - U.S. equities are showing a cautious and mixed performance as investors await the Federal Reserve's interest rate decision, with major indexes hovering near flat lines [1][4]. Market Performance - The S&P 500 is up 0.2%, the Nasdaq Composite has increased by 0.3%, and the Dow Jones Industrial Average is leading with a 0.3% gain, reflecting a "wait-and-see" approach ahead of the Fed announcement [2][4]. Sector Performance - The energy sector is leading gains, while the utilities sector is also performing well. However, some areas face challenges, particularly the "Magnificent Seven" tech stocks, which are under increased competitive pressure [3][4]. Federal Reserve Meeting - The Federal Open Market Committee (FOMC) meeting is the primary focus, with expectations for a third consecutive quarter-point interest rate cut, with probabilities between 87% and 89.6% for this outcome [4][5]. Economic Data - The October Job Openings and Labor Turnover Survey (JOLTS) reported 7.67 million job openings, exceeding expectations of 7.2 million, which will influence the Fed's deliberations [6]. Corporate Earnings - AutoZone, Inc. shares fell by 6.7% after weaker-than-expected first-quarter results, while Home Depot shares slipped about 0.5% due to disappointing fiscal projections [7]. Major Stock News - Nvidia (NVDA) shares dipped 0.4% despite approval for limited sales of its H200 AI chips to China. Alphabet (GOOGL) stock rose by 1.3% amid a European Commission probe, while CVS Health (CVS) shares advanced 3% after raising full-year guidance [8][9][10]. Investment Highlights - Microsoft (MSFT) announced a $17.5 billion investment in India for AI development, and Structure Therapeutics (GPCR) saw a price target increase to $130 after positive drug data [10][11]. Exxon Mobil (XOM) climbed 3.4% after raising its profit forecast [12].

Zentalis Pharmaceuticals ( ZNTL ) is a microcap biotech developer of targeted therapies within the space of DNA damage repair. After a recent restructuring, they are focusing all effort on the late-stage development of one drug. However, theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not ge ...

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics centers on allegations that the company misrepresented the clinical efficacy of its Nanobody structure compared to traditional monoclonal antibodies, particularly in the context of the Phase 3 VELA trials [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that its product SLK shares the same molecular targets as BIMZELX, a competitor, which undermines its claimed competitive advantage [3]. - Allegations include that the company misrepresented the Nanobody's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Financial Impact - Investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and experienced significant losses are encouraged to participate in the lawsuit [4]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors in similar cases, indicating a strong potential for recovery [4][7]. Next Steps for Investors - The deadline for investors to move for appointment as lead plaintiff in the class action lawsuit is December 15, 2025 [1][5]. - Investors are urged to contact Hagens Berman for more information and to discuss their losses related to MoonLake [5][6].

Core Insights - Exicure, Inc. (NASDAQ:XCUR) stock experienced a significant increase of 63.23%, reaching $8.70, following the announcement of positive results from its Phase 2 trial of burixafor in multiple myeloma patients [6] Group 1: Trial Results - Approximately 90% of study participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Among the 19 participants, 17 (89.5%) met the primary endpoint, with two requiring an additional session to achieve the target [3] - The median time to neutrophil engraftment was 13 days, and the median time to platelet engraftment was 17.5 days for those who proceeded to transplant [4] Group 2: Mechanism and Efficacy - Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors, facilitating rapid mobilization of hematopoietic progenitor cells from the bone marrow [2] - The combination of burixafor with propranolol enhanced mobilization by inhibiting the β2-adrenergic receptor [3] - Peak peripheral levels of CD34+ cells were observed within one hour of burixafor administration, allowing for same-day administration and apheresis [4] Group 3: Safety Profile - The burixafor combination was well tolerated, with no related adverse events exceeding Grade 2 [6] - Among participants with prior exposure to daratumumab, 87.5% achieved the primary endpoint, indicating the treatment's effectiveness even in previously treated patients [5]

Financial Performance & Growth - Ligand预计2025年版税收入超过1.5亿美元，同比增长约40%[5] - Ligand预计2025年核心收入为2.25亿美元至2.35亿美元[39] - Ligand预计2025年调整后核心每股收益为7.40美元至7.65美元，同比增长约31%[40] - Ligand预计2025年运营现金流约为1.75亿美元[41] - Ligand预计2026年版税收入为2亿美元至2.25亿美元，同比增长约40%[45] - Ligand预计2026年总收入为2.45亿美元至2.85亿美元，同比增长约15%[45] - Ligand预计2026年调整后核心每股收益为8.00美元至9.00美元，同比增长约13%[45] - Ligand预计2025-2030年版税收入复合年增长率达到或超过23%[7] Investment & Portfolio - Ligand拥有约10亿美元的可部署资本，包括约6.65亿美元的现金和投资[5] - Ligand在过去两年中已承诺超过4亿美元用于11项投资[82] - Ligand审查了超过170项投资，签署了69项保密协议，完成了6项投资[5, 81]